Table 1.
Response rates of RS4;11-LMC in xenograft and systemic engraftment models to Bcl inhibitors and standard of care agents
| Treatment | Dose (mg/kg per day) | SC xenograft | IV systemic | |||
|---|---|---|---|---|---|---|
| Schedule | %TGD1 | Schedule | %TGD1 | %TGD1 (+navit) | ||
| Navitoclax | 100 | p.o. q.d. × 7 | >1333 | p.o. q.d. × 14 | 573 | N/A |
| Venetoclax | 100 | p.o. q.d. × 7 | >1333 | p.o. q.d. × 14 | 673 | N/A |
| Cyclophosphamide | 100 | i.p. q.4d. × 4 | 1273 | i.p. q.4d. × 4 | 1363 | 2004 |
| Cyclophosphamide2 | 25 | i.p. q.d. × 1 | 673 | i.p. q.d. × 1 | 143 | 864 |
| Doxorubicin | 3 | i.v. q.d. × 1 | i.v. q.d. × 1 | |||
| Vincristine | 0.25 | i.v. q.d. × 1 | i.v. q.d. × 1 | |||
| Prednisolone | 0.5 | p.o. q.d. × 1 | p.o. q.d. × 1 | |||
| Bendamustine | 25 | i.v. q.d. × 1 | 193 | i.v. q.d. × 1 | 0 | 57 |
| 25 | i.v. q.7d. × 2 | 293 | i.v. q.7d. × 2 | −6 | 464 | |
1
% Tumor growth delay.
2
Representative of CHOP. All four agents administered on d1, spaced 90 min apart in order shown.
3
P < 0.05 versus vehicle control (Kaplan–Meier log rank test).
4
P < 0.05 versus cytotoxic(s) (Kaplan–Meier log rank test).